Actemra® (tocilizumab)

BL 125276 [BL 125472]

Actemra® (tocilizumab)

BL 125276 [BL 125472]

U.S. License Holder:

Genentech

Date of License:

January-08-2010 [October-21-2013]

Last Update:

October-23-2021

approved_indications FDA-Approved Indications

ACTEMRA (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

Rheumatoid Arthritis (RA): Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs);

Giant Cell Arteritis (GCA): Adult patients with giant cell arteritis;

Polyarticular Juvenile Idiopathic Arthritis (PJIA): Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis;

Systemic Juvenile Idiopathic Arthritis (SJIA): Patients 2 years of age and older with active systemic juvenile idiopathic arthritis;

Cytokine Release Syndrome (CRS): Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2021-01024

U.S. Patent No.
7,521,052 (Methods for Treating Interleukin-6 Related Diseases)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

IPR2021-01025

U.S. Patent No.
10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

IPR2021-01288

U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

IPR2021-01336

U.S. Patent No.
10,874,677 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Other (Drug Delivery Device)

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Other (Drug Delivery Device)

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

IPR2021-01542

U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

related articles Related News Articles

Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D. October 12, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D. September 8, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong July 13, 2021

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha